• Overview
  • Eligibility
  • More info
  • Locations

Matched Unrelated and Haploidentical Bone Marrow Transplantation for Hematologic Malignancies (NCT00003960)

National Cancer Institute (NCI)
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Bone marrow transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy plus donor bone marrow transplantation in treating patients who have hematologic cancer.
  • Drug: busulfan
    • Drug: cyclophosphamide
      • Drug: methylprednisolone
        • Procedure: allogeneic bone marrow transplantation
          • Procedure: in vitro-treated bone marrow transplantation
            Ages eligible for Study
            19 Years to 55 Years
            Genders eligible for Study
            All
            Accepts Healthy Volunteers
            No
            OBJECTIVES: I. Determine the 1-year survival rate of patients with hematologic malignancies after treatment with HLA-matched allogeneic bone marrow transplantation after high-dose chemotherapy.

            OUTLINE: Patients receive oral busulfan four times a day on days -8 to -5, cyclophosphamide IV over 1 hour on days -4 to -1, and methylprednisolone IV over 1 hour every 12 hours on days -2 to 0. CD34+ stem cell augmented donor bone marrow is infused on day 0. Methylprednisolone is administered IV over 1 hour on days 5-16, and then tapered. Patients are followed every 6 months for 1 year and then annually thereafter.

            PROJECTED ACCRUAL: A total of 36 patients will be accrued for this study within 3 years.

            2 locations

            United States (2)
            • Johns Hopkins Oncology Center
              Not specified
              Baltimore, Maryland, United States, 21231
            • Center for Cancer Treatment and Research
              Not specified
              Columbia, South Carolina, United States, 29203
            Status:
            completed
            Type:
            Interventional
            Phase:
            Start:
            31 March, 1998
            Updated:
            30 April, 2014
            Participants:
            36
            A girl giving information about available additional trials.

            FindMeCure helps you find, understand and join clinical trials from all over the world.

            There are more clinical trials for your condition!